<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03421184</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/18</org_study_id>
    <nct_id>NCT03421184</nct_id>
  </id_info>
  <brief_title>Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus</brief_title>
  <acronym>ISOLED</acronym>
  <official_title>Dietary Phytoestrogens in Blood and Urine of Female Patient With Acute Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims at determining if dietary phytoestrogens can be risk factors for Systemic
      Lupus Erythematosus (SLE). Dietary enquiry and phytoestrogens measurements will be performed
      in blood and urine of patients with SLE in an active phase of the disease, in patient with
      other autoimmune diseases and in healthy volunteers. Subjects will be premenopausal women and
      when possible at a define stage of the menstrual cycle. Free blood estradiol will be assayed
      as a confounding risk factor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SLE is a disease occurring in 90% of the cases in pre-menopausal women. The causing factors
      are largely unknown even though genetic and environmental factors have already been
      identified. Estrogens, on one side, have been shown to negatively influence the incidence and
      severity of the disease while testosterone and progesterone on the other side are thought to
      be protective. Endocrine disruptors can potentially influence the occurrence and severity of
      the disease. Among these disruptors, soy isoflavones which are ubiquitous in modern processed
      food are known to be estrogenic and anti-androgenic. Their depleting effect on luteinizing
      hormone (LH) secretion can also lead to progesterone plasma level impairments. For these
      reasons, estrogenic isoflavones, appear as potential environmental risk factors for SLE and
      its flares. Although some data exist in transgenic rodent, there is actually no clinical data
      in young women.

      The study is an observational, monocentric, preliminary study aiming at determining if
      estrogenic isoflavones can be risk factors for SLE. No treatment is planned. The intervention
      will be the collection of extra blood and urine samples on SLE subjects and on autoimmune and
      healthy counterparts.

      Consumers are unintentionally exposed to estrogenic isoflavones through their diet. A dietary
      habit enquiry and a 48h dietary recall (based on pharmacokinetics of soy-isoflavones) will be
      proposed to the included subjects. Urine and blood samples collected during a clinical visit
      performed 7 days after the onset of previous menses will be analyzed for soy isoflavones,
      metabolites and for enterolactone both free and conjugated. Free estradiol will be assayed as
      a potential confounding risk factor.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of different isoflavones and enterolactone</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>in the blood and urine of patients and healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of free estradiol concentrations</measure>
    <time_frame>At baseline (day 0)</time_frame>
    <description>in the blood and urine of patients and healthy controls</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Lupus Erythematosus</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Autoimmune Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Patient with Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 women with SLE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with other autoimmune diseases</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients with rheumatoid arthritis, 20 patients with autoimmune thrombocytopenia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 healthy control women</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>25 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>Patient with Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_label>Patients with other autoimmune diseases</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>urine sample</intervention_name>
    <description>10 ml</description>
    <arm_group_label>Patient with Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_label>Patients with other autoimmune diseases</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>food questionnaire</intervention_name>
    <description>dietary habit enquiry and a 48h dietary</description>
    <arm_group_label>Patient with Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_label>Patients with other autoimmune diseases</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>hair</intervention_name>
    <description>lock of hair</description>
    <arm_group_label>Patient with Systemic Lupus Erythematosus</arm_group_label>
    <arm_group_label>Patients with other autoimmune diseases</arm_group_label>
    <arm_group_label>Healthy control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group : Systemic Lupus Erythematosus :

               -  Premenopausal women over 18

               -  with acute LEAD flare

               -  having given informed consent

               -  and being covered by social insurance.

          -  Group : Autoimmune diseases :

               -  Premenopausal women of matching age with other autoimmune disease,

               -  having given informed consent

               -  and being covered by social insurance.

          -  Healthy controls :

               -  Premenopausal women over 18,

               -  having given informed consent,

               -  and being covered by social insurance.

        Exclusion Criteria:

          -  Group Systemic Lupus Erythematosus and group autoimmune diseases

               -  Human Immunodeficiency virus (HIV), hepatitis C virus (HCV) or hepatitis C virus
                  (HBV) sero-positivity;

               -  pregnant or lactating women;

               -  menopausal women;

               -  patient in remission of quiescent phase of her pathology;

          -  Healthy controls :

               -  HIV, HCV or HBV sero-positivity;

               -  pregnant or lactating women;

               -  menopausal women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François VIALLARD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU - Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François VIALLARD, Prof</last_name>
    <phone>05.57.65.64.83</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-françois.viallard@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabelle RAYMOND, Pharm</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de médecine interne</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <phone>05.57.65.64.83</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-françois.viallard@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Isabelle RAYMOND, Pharm</last_name>
    </contact_backup>
    <investigator>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estibaliz LAZARO, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Luc PELLEGRIN, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carine GREIB, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irene MACHELARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marion MIRABEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Etienne RIVIERE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry SCHAEVERBEKE, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe RICHEZ, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Elise TRUCHETET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas POURSAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia MEHSEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2018</study_first_submitted>
  <study_first_submitted_qc>January 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2018</study_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>autoimmune disease</keyword>
  <keyword>endocrine disruptors</keyword>
  <keyword>isoflavones</keyword>
  <keyword>lignans</keyword>
  <keyword>diet exposure</keyword>
  <keyword>risk factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phytoestrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

